Drawing for FERTIN

USPTO serial 99527265

FERTIN

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
HOPKINS, SARAH COLLEEN
Law office
TMO LAW OFFICE 123

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FERTIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tamar Niv Bessinger

Tamar Niv Bessinger Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th FloorNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of a wide variety of diseases and conditions, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders in chewable form, in gum form, in lozenge form, and in pouch powder form; pharmaceutical preparations for smoking cessation; aerosolized and inhaled therapeutics and pharmaceuticals for the treatment of a wide variety of diseases and conditions, namely, smoking cessation preparations, analgesic preparations, sleep aid- preparations, anti-pyretic and anti-inflammatory preparations, preparations for the treatment of arthritis, preparations having psychotherapeutic properties, preparations for treatment of cold, flu, cough, sinus, allergy, cardiovascular emergencies, neurological conditions, chronic pain management, and gastro-intestinal disorders; drug delivery agents in the form of fast liquefiable tablets, compressed gum, extruded gum, lozenges, pouch powder, dissolvable films, coatings for tablets, and transdermal patches that facilitate the delivery of pharmaceutical preparations; vitamins and dietary supplements; nicotine chewing gum for medical purposes; nicotine gum for use as an aid to stop smokingACTIVE—
040Custom manufacturing services for pharmaceuticals and nutraceuticals; contract manufacturing services being custom manufacturing of pharmaceuticals and nutraceuticals; processing of pharmaceutical preparations being processing of medicinal plants for pharmaceutical preparations; processing of medicinal plants for nutraceutical preparations; formulation services being custom manufacture of pharmaceuticals and nutraceuticals; custom manufacture of pharmaceuticals involving blending, granulation, encapsulation, tableting, and coating of pharmaceuticals and nutraceuticals; advisory and consultancy services relating to the aforesaidACTIVE—
042Research and development services for pharmaceuticals and nutraceuticals formulation, research, and development of pharmaceutical preparations for treatment of a wide variety of diseases and conditions in chewable form, in gum form, in lozenge form, and in pouch powder form; formulation, research, and development of inhaled therapeutics; research, and development of pharmaceutical and well-being products being nutritional supplements for oral and intra-oral delivery systems; research, and development of pharmaceuticals for smoking cessation; provision of advice in the field of new product design; analytical testing and quality control services, namely, product quality testing services; stability testing, namely, product quality testing services involving stability of product; medical research laboratory services for pharmaceuticals and nutraceuticals; consultancy in the field of pharmaceutical and nutraceutical research; design and development of new drug delivery system products; advisory and consultancy services relating to the aforesaidACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 6, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jul 6, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Jul 6, 2026CNSLSUSPENSION LETTER WRITTEN—
Jul 1, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 1, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 1, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 5, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 5, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 5, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 25, 2026DOCKASSIGNED TO EXAMINER—
Apr 24, 2026MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 24, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 3, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 3, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance